Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us
Conference Highlights
San Antonio Breast Cancer Symposium (SABCS)
SABCS 2017
SABCS 2017
Combined Inhibition of mTOR and CDK4/6 Is Required for Optimal Blockade of E2F Function and Long-Term Growth Inhibition in ER-Positive Breast Cancer
SABCS 2017
Triplet therapy consisting of an mTOR inhibitor, a CDK4/6 inhibitor, and an estrogen receptor (ER) antagonist such as fulvestrant may be optimal in treating hormone receptor–positive metastatic breast cancer, especially in the setting of CDK4/6-resistant tumors.
Read More ›
Everolimus/Exemestane versus Palbociclib/Fulvestrant, Abemaciclib/Fulvestrant, or Everolimus/Fulvestrant in Treating MBC
SABCS 2017
A comparison of the relative efficacy of combination hormone therapies in hormone receptor‒ positive/HER2-negative metastatic breast cancer (MBC) suggests that everolimus/exemestane may be the most effective treatment option available.
Read More ›
Videos
CDK4/6 Inhibitors vs Chemotherapy for Patients with Metastatic Breast Cancer
SABCS 2017
Despite international guidelines and data that show CDK4/6 inhibitors plus aromatase inhibitors can improve overall response rates, overall survival, and progression-free survival in patients with metastatic breast cancer, there is a lasting belief among patients that chemotherapy is the preferable course of treatment. Dr. Hope Rugo attempts to dispel this misconception, citing that endocrine therapy and CDK4/6 inhibitors are well tolerated and don’t have the intensive side effects associated with chemotherapy.
Read More ›
Videos
CDK4/6 Inhibitors in HER2+ Metastatic Breast Cancer
SABCS 2017
Dr Matthew Goetz addresses the prospect of utilizing CDK4/6 inhibitors to treat patients with HER2+ metastatic breast cancer, stating early data indicate that CDK4/6 inhibitors may have some antitumor activity in HER2+ breast cancer.
Read More ›
Xentuzumab and Abemaciclib plus Endocrine Therapy in Locally Advanced/Metastatic Breast Cancer
SABCS 2017
The phase 1b trial of the insulin-like growth factor ligand-neutralizing antibody xentuzumab and the CDK4/6 inhibitor abemaciclib, plus endocrine therapy, is designed to evaluate safety, tolerability, and preliminary efficacy in patients with locally advanced or metastatic hormone receptor (HR)-positive/HER2-negative breast cancer.
Read More ›
Loss of Mismatch Repair Predicts Resistance to Endocrine Therapy and Sensitivity to CDK4/6 Inhibitors in ER-Positive Breast Cancer
SABCS 2017
Although there are currently no biomarkers to guide the use of CDK4/6 inhibitors for estrogen receptor (ER)-positive breast cancer, markers of mismatch repair dysregulation could identify patients in whom CDK4/6 inhibition may prevent disease recurrence most effectively.
Read More ›
Therapeutic Targeting of CDK4/6 Inhibitor–Resistant Breast Cancer
SABCS 2017
An underlying mechanism of combined endocrine therapy and CDK4/6 inhibitor resistance in hormone receptor–positive breast cancer is senescent escape, and 2 novel therapeutic strategies have been identified for this disease, including MDM2 inhibition and CDK2 activation.
Read More ›
CDK6 Could Be a Key Factor for Efficacy of CDK4/6 Inhibitors and the Hormone Sensitivity Following Acquired Resistance
SABCS 2017
CDK6 may be a useful biomarker in patients with estrogen receptor–positive breast cancer who develop acquired resistance to CDK4/6 inhibitors, and inhibition of the PI3K/Akt/mTOR pathway may be a reasonable therapeutic approach for these patients.
Read More ›
New Oral SERD Elacestrant Shows Efficacy in Breast Cancer Harboring ESR1 Mutations
SABCS 2017
The new oral selective estrogen receptor degrader (SERD) elacestrant demonstrates potent antitumor activity in in vitro models, with additive effects to CDK4/6 inhibitors.
Read More ›
Videos
The Mechanism of Action of CDK4/6 Inhibitors
SABCS 2017
Dr Matthew Goetz explains the rationale for using CDK4/6 inhibitors in patients with HR-positive metastatic breast cancer.
Read More ›
Page 3 of 4
1
2
3
4
Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us